Fount Subscription Economy ETF Fount Subscription Economy ETF SUBS 深 沪
等待开盘 02-05 09:30:00 美东时间
19.00
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 19.00
- 总市值 190.00万
- 52周最高 19.492
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 15.5433
- 委 比 0.00%
- 总股本 10.00万
- 历史最高 25.4237
- 量 比 0
- 振 幅 0.00%
- 历史最低 15.5433
- 每 手 1
- 风险率 0.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-Nukkleus Inc - Subsidiary Rimon Secures Multi-Year Defense Contracts - SEC Filing
BRIEF-Nukkleus Inc - Subsidiary Rimon Secures Multi-Year Defense Contracts - SEC Filing Feb 3 (Reuters) - Nukkleus Inc NUKK.O : NUKKLEUS INC - SUBSIDIARY RIMON SECURES MULTI-YEAR DEFENSE CONTRACTS - SEC FILING NUKKLEUS INC - CONTRACTS VALUED AT ABOUT $4.1 MILLION - SEC FILING Source text: [ID:n00012
02-03 21:51
BRIEF-Aemetis India Subsidiary Begins Biodiesel Deliveries Under $24 Million Allocation From Omcs
BRIEF-Aemetis India Subsidiary Begins Biodiesel Deliveries Under $24 Million Allocation From Omcs Feb 3 (Reuters) - Aemetis Inc AMTX.O : AEMETIS INDIA SUBSIDIARY BEGINS BIODIESEL DELIVERIES UNDER $24 MILLION ALLOCATION FROM OMCS Source text: ID:nGNX420ZCB Further company coverage: AMTX.O (( Reuters.
02-03 21:23
BRIEF-Enorama Pharma Subsidiary Intends To Appeal FDA's Refuse-To-File Decision
BRIEF-Enorama Pharma Subsidiary Intends To Appeal FDA's Refuse-To-File Decision Feb 3 (Reuters) - Enorama Pharma AB ERMA.ST : SUBSIDIARY INTENDS TO APPEAL FDA'S RTF DECISION COMPANY IN CONTACT WITH FDA FOR CLARITY ON REGULATORY STATUS ANALYZING FDA DECISION AND EVALUATING CONSEQUENCES Source text: I
02-03 17:33
BRIEF-Arcos Dorados Says Brazilian Subsidiary Borrows $150 Mln
BRIEF-Arcos Dorados Says Brazilian Subsidiary Borrows $150 Mln Feb 2 (Reuters) - Arcos Dorados Holdings Inc ARCO.N : ARCOS DORADOS INCREASES THE EFFICIENCY OF ITS CAPITAL STRUCTURE ARCOS DORADOS HOLDINGS INC - BRAZILIAN SUBSIDIARY BORROWS $150 MILLION ARCOS DORADOS HOLDINGS INC - PROCEEDS TO FUND $1
02-02 21:52
BRIEF-Sanegenebio Announces Rnai Global Licensing Collaboration With Genentech
BRIEF-Sanegenebio Announces Rnai Global Licensing Collaboration With Genentech Feb 2 (Reuters) - SANEGENEBIO ANNOUNCES RNAI GLOBAL LICENSING COLLABORATION WITH GENENTECH SANEGENEBIO-WILL RECEIVE UPFRONT PAYMENT OF $200 MILLION, WILL BE ELIGIBLE TO RECEIVE DEVELOPMENT, COMMERCIALIZATION MILESTONE PAY
02-02 21:03
BRIEF-Voestalpine AG - Sells Subsidiary Böhler Profil To Kadant
BRIEF-Voestalpine AG - Sells Subsidiary Böhler Profil To Kadant Jan 29 (Reuters) - VOESTALPINE AG VOES.VI : VOESTALPINE AG - TRANSACTION IS EXPECTED TO BE COMPLETED BY THE END OF THE 2025/2026 FINANCIAL YEAR VOESTALPINE AG - SELLS SUBSIDIARY BÖHLER PROFIL TO US INDUSTRIAL COMPANY KADANT INC. Further
01-29 21:30
BRIEF-Tesla To Invest About $2 Billion To Acquire Shares Of Series E Preferred Stock Of xAI
BRIEF-Tesla To Invest About $2 Billion To Acquire Shares Of Series E Preferred Stock Of xAI Jan 28 (Reuters) - Tesla Inc TSLA.O : TESLA INC Q4 REVENUE $24,901 MILLION VERSUS IBES ESTIMATE $24,790 MILLION TESLA INC Q4 GROSS MARGIN 20.1% TESLA INC: IN 2026, WE WILL FURTHER INVEST IN THE INFRASTRUCTURE
01-29 06:26
Manhattan Associates Q4 revenue and EPS beat estimates
Manhattan Associates Q4 revenue and EPS beat estimates Overview Supply chain solutions provider's Q4 revenue rose, beating analyst expectations Adjusted EPS for Q4 beat analyst expectations Company repurchased 415,925 shares for $75 mln in Q4 Outlook Manhattan Associates forecasts 2026 revenue betwe
01-28 05:15
Commvault Q3 revenue beats estimates on demand for AI-enabled platforms
Commvault Q3 revenue beats estimates on demand for AI-enabled platforms Overview Data protection firm's fiscal Q3 revenue rose 19% yr/yr, beating analyst expectations Adjusted EPS for fiscal Q3 beat analyst expectations Company's ARR grew 22% yr/yr, reaching $1,085 mln Outlook Commvault expects Q4 r
01-27 20:54
Agilysys Q3 revenue up 15.6%, beats estimates
Agilysys Q3 revenue up 15.6%, beats estimates Overview Hospitality software provider's fiscal Q3 revenue rose 15.6%, beating analyst expectations Adjusted EPS for fiscal Q3 missed analyst expectations Company raised full-year fiscal 2026 revenue guidance to $318 mln Outlook Agilysys raises full-year
01-27 05:13
